Investigating how certain molecular features affect treatment response in advanced prostate cancer
Molecular features promoting sensitivity to LSD1i in castration-resistant prostate cancer
This study is looking at why some advanced prostate cancers, especially neuroendocrine prostate cancer, respond better to a new treatment called LSD1 inhibitor, with the goal of finding ways to make treatments more effective for men facing this tough type of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11043340 on NIH RePORTER |
What this research studies
This research focuses on understanding the molecular characteristics that make certain types of advanced prostate cancer, specifically neuroendocrine prostate cancer (NEPC), more sensitive to a new treatment called LSD1 inhibitor. By analyzing genetic and epigenetic features, the researchers aim to identify why NEPC responds better to this treatment compared to other prostate cancer subtypes. The study will utilize comprehensive genome-scale analyses and pharmacogenomics to develop a targeted approach that could improve treatment outcomes for patients. If successful, this could lead to more effective therapies for men suffering from this aggressive form of cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with metastatic castration-resistant prostate cancer, particularly those with neuroendocrine features.
Not a fit: Patients with early-stage prostate cancer or those who do not have metastatic disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted treatments for patients with advanced prostate cancer, potentially improving survival rates.
How similar studies have performed: Previous research has shown promising results with similar targeted therapies in other cancer types, indicating potential for success in this approach.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Brennen, William Nathaniel — Johns Hopkins University
- Study coordinator: Brennen, William Nathaniel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.